Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2020-10-01 Board/Management Inform…
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically details the appointment of a new board member, Alison Lawton, including her background, committee assignments, and compensation. There is no financial data or report attached; rather, it is an announcement of a change in the company's board of directors. This matches the description of 'Board/Management Information' filings, which cover announcements of changes in the company's board or senior management. The document length (7141 characters) supports it being a full announcement rather than a brief notice. Therefore, the appropriate classification is MANG (Board/Management Information).
2020-10-01 English
FORM 4
Director's Dealing
2020-09-22 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the resignation of the Chief Scientific Officer and the commencement of a search for a replacement. This is an announcement of a change in senior management. There are no financial statements or detailed financial data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement or regulatory filing in the sense of certifications. The document fits the category of Board/Management Information (MANG) as it announces a change in senior management.
2020-09-11 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-09-10 English
FORM 4
Director's Dealing
2020-09-10 English
FORM 4
Director's Dealing
2020-09-10 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.